28 research outputs found
Arginase inhibition alleviates hypertension in the metabolic syndrome
BACKGROUND AND PURPOSE: We have previously shown that arginase inhibition alleviates hypertension associated with in a diabetic animal model. Here, we investigated the protective effect of arginase inhibition on hypertension in metabolic syndrome. EXPERIMENTAL APPROACH: Metabolic syndrome was induced in rats by administration of fructose (10% in drinking water) for 12 weeks to induce vascular dysfunction. Three arginase inhibitors (citrulline, norvaline and ornithine) were administered daily in the last 6 weeks of study before and tail BP was recorded in conscious animals. Concentration response curves for phenylephrine (PE), KCl and ACh in addition to ACh-induced NO generation were obtained in thoracic aorta rings. Serum glucose, insulin, uric acid and lipid profile were determined as well as reactive oxygen species (ROS) and arginase activity. KEY RESULTS: Arginase activity was elevated in metabolic syndrome while significantly inhibited by citrulline, norvaline or ornithine treatment. Metabolic syndrome was associated with elevations in systolic and diastolic BP, while arginase inhibition significantly reduced elevations in diastolic and systolic BP. Metabolic syndrome increased vasoconstriction responses of aorta to PE and KCl and decreased vasorelaxation to ACh, while arginase inhibition completely prevented impaired responses to ACh. In addition, arginase inhibition prevented impaired NO generation and exaggerated ROS formation in metabolic syndrome. Furthermore, arginase inhibition significantly reduced hyperinsulinaemia and hypertriglyceridaemia without affecting hyperuricaemia or hypercholesterolaemia associated with metabolic syndrome. CONCLUSIONS AND IMPLICATIONS: Arginase inhibition alleviates hypertension in metabolic syndrome directly through endothelial-dependent relaxation/NO signalling protection and indirectly through inhibition of insulin resistance and hypertriglyceridaemia
Modulation of preeclampsia by the cholinergic anti-inflammatory pathway: Therapeutic perspectives
The cholinergic anti-inflammatory pathway (CAP) is vital for the orchestration of the immune and inflammatory responses under normal and challenged conditions. Over the past two decades, peripheral and central circuits of CAP have been shown to be critically involved in dampening the inflammatory reaction in a wide array of inflammatory disorders. Additionally, emerging evidence supports a key role for CAP in the regulation of the female reproductive system during gestation as well as in the advent of serious pregnancy-related inflammatory insults such as preeclampsia (PE). Within this framework, the modulatory action of CAP encompasses the perinatal maternal and fetal adverse consequences that surface due to antenatal PE programming. Albeit, a considerable gap still exists in our knowledge of the precise cellular and molecular underpinnings of PE/CAP interaction, which hampered global efforts in safeguarding effective preventive or therapeutic measures against PE complications. Here, we summarize reports in the literature regarding the roles of peripheral and reflex cholinergic neuroinflammatory pathways of nicotinic acetylcholine receptors (nAChRs) in reprogramming PE complications in mothers and their progenies. The possible contributions of α7-nAChRs, cholinesterases, immune cells, adhesion molecules, angiogenesis, and endothelial dysfunction to the interaction have also been reviewed.Supported by the Science and Technology Development Fund, Egypt (STDF Grant No. 14895)
Phenolics from Garcinia mangostana alleviate exaggerated vasoconstriction in metabolic syndrome through direct vasodilatation and nitric oxide generation
Chrysin and Luteolin Alleviate Vascular Complications Associated with Insulin Resistance Mainly Through PPAR-γ Activation
Gingerol Synergizes the Cytotoxic Effects of Doxorubicin against Liver Cancer Cells and Protects from Its Vascular Toxicity
Hydroxyphenylalkanes and diarylheptanoids possess potential therapeutic value in different pathophysiological conditions, such as malignancy. In the current study, naturally isolated hydroxyphenylalkane and diarylheptanoid compounds were investigated for potential chemo-modulatory effects in addition to potential vascular protective roles with doxorubicin. Diarylheptanoids showed stronger antioxidant effects, in comparison to hydroxyphenylalkanes, as demonstrated by DPPH assay and amelioration of CCl4-induced disturbed intracellular GSH/GSSG balance. Shogaol and 4′-methoxygingerol showed considerable cytotoxic effects against HCT116, HeLa, HepG2 and MCF7 cells, with IC50 values ranging from 3.1 to 19.4 µM. Gingerol significantly enhanced the cytotoxic profile of doxorubicin against HepG2 and Huh7, cells decreasing its IC50s by 10- and 4-fold, respectively. Cell cycle distribution was studied using DNA cytometry. Doxorubicin alone induced cell accumulation at S-phase and G2/M-phase, while in combination with gingerol it significantly induced cell cycle arrest at the G2/M-phase. Additionally, the vascular protective effect of gingerol against doxorubicin (10 µM) was examined on isolated aortic rings. Co-incubation with 6-gingerol (30 µM) completely blocked the exaggerated vasoconstriction and impaired vascular relaxation induced by doxorubicin. In conclusion, despite its relatively weak antioxidant properties, gingerol protected from DOX-induced vascular damage, apparently not through a ROS scavenging mechanism. Besides, gingerol synergized the cytotoxic effects of DOX against liver cancer cells without influencing the cellular pharmacokinetics
Pentoxifylline alleviates hypertension in metabolic syndrome: effect on low-grade inflammation and angiotensin system
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis
Poly(ADP-ribose) polymerase (PARP) enzyme
contributes to nephropathy, a serious diabetic complication
which may lead to end-stage renal disease. The study aims
to investigate the effect of PARP over-activation on kidney
functions in a type 2 diabetic rat model. The study also tests
the therapeutic use of PARP inhibitors in diabetic nephropathy.
Type 2 diabetes was induced in adult male rats by highfructose/high-fat
diet and low streptozotocin dose. Then, the
PARP inhibitor 4-aminobenzamide (4-AB) was administered
daily for 10 weeks. At the end, urine samples were collected to
measure urine creatinine, albumin, and total proteins. PARP
activity, superoxide dismutase (SOD) activity, and nitrite content
were measured in kidney tissue homogenate. Glucose,
fructosamine, insulin, and tumor necrosis factor-alpha
(TNF-α) were measured in serum. Furthermore, histological
studies, collagen deposition, and immunofluorescence of nuclear
factor kappa B (NFκB) and transforming growth factor
beta1 (TGF-β1) were carried out. PARP enzyme activity was
significantly higher in the diabetic group and was significantly
reduced by 4-AB administration. Diabetic animals had clear
nephropathy indicated by proteinuria and increased albumin
excretion rate (AER) which were significantly decreased by
PARP inhibition. In addition, PARP inhibition increased creatinine
clearance in diabetic animals and reduced renal
TGF-β1 and glomerular fibrosis. Moreover, PARP inhibition
alleviated the elevated serum TNF-α level, renal NFκB, nitrite,
and the decrease in SOD activity in diabetic animals.
However, PARP inhibition did not significantly affect neither
hyperglycemia nor insulin sensitivity. PARP enzyme inhibition
alleviates diabetic nephropathy through decreasing inflammation,
oxidative stress, and renal fibrosi